Michael Gelband’s MoonLake Immunotherapeutics MLTX Stock Holding History

Michael Gelband’s Portfolio MLTX Stock Details MLTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$908K	Sell	46,646 -73,664	-61%	-$1.34M	0.01%	1101
2026 Q1	$2.24M	Sell	120,310 -92,686	-44%	-$1.54M	0.02%	746
2025 Q4	$2.81M	Buy	+212,996	New	+$2.51M	0.02%	658
2025 Q3	–	Sell	-25,313	Closed	-$1.32M	–	1840
2025 Q2	$1.2M	Buy	+25,313	New	+$1.03M	0.01%	905
2024 Q4	–	Sell	-16,855	Closed	-$850K	–	1841
2024 Q3	$850K	Buy	+16,855	New	+$790K	0.01%	1013
2024 Q1	–	Sell	-28,417	Closed	-$1.72M	–	1793
2023 Q4	$1.72M	Sell	28,417 -16,764	-37%	-$864K	0.01%	629
2023 Q3	$2.58M	Buy	+45,181	New	+$2.49M	0.02%	598
2022 Q1	–	Sell	-25,200	Closed	-$249K	–	2494
2021 Q4	$249K	Buy	25,200 +200	+0.8%	+$1.99K	﹤0.01%	1728
2021 Q3	$247K	Hold	25,000	–	–	﹤0.01%	1698
2021 Q2	$259K	Hold	25,000	–	–	﹤0.01%	1828
2021 Q1	$255K	Sell	25,000 -9,551	-28%	-$105K	﹤0.01%	1760
2020 Q4	$393K	Buy	+34,551	New	+$367K	﹤0.01%	1393

Other funds holding MLTX

BVF Inc San Francisco, California $3.91B AUM 304.52% 1-Year Est. Return

DTC

Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return

T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return

D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return

CAM

Cormorant Asset Management Boston, Massachusetts $1.95B AUM 773.9% 1-Year Est. Return

Jupiter Topco New York $245B AUM

LGM

Logos Global Management San Francisco, California $2.32B AUM 536.01% 1-Year Est. Return

WAM

Weiss Asset Management Boston, Massachusetts $9.54B AUM 55.06% 1-Year Est. Return

Citadel Advisors Miami, Florida $875B AUM 40.91% 1-Year Est. Return

Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return

Michael Gelband's MLTX Position: Q2 2026 in Review

Michael Gelband reduced its MoonLake Immunotherapeutics (MLTX) stake by 61% in Q2 2026, selling an estimated $1.34M and leaving 46,646 shares worth $908K. The position accounts for 0.01% of the portfolio, ranked #1101.

Michael Gelband first reported a position in MLTX in Q4 2020 and has held it in 12 quarters since. The position peaked at $2.81M in Q4 2025. 171 funds tracked by Wall St. Rank hold MLTX as of Q2 2026.

Michael Gelband held 46,646 shares of MoonLake Immunotherapeutics worth $908K as of Q2 2026.
Michael Gelband sold 73,664 MoonLake Immunotherapeutics shares in Q2 2026, an estimated $1.34M.
MoonLake Immunotherapeutics made up 0.01% of Michael Gelband's portfolio in Q2 2026, its #1101 holding.
Michael Gelband first reported a position in MoonLake Immunotherapeutics in Q4 2020 and has held it in 12 quarters since.
Michael Gelband's MoonLake Immunotherapeutics position peaked at $2.81M in Q4 2025.
171 funds tracked by Wall St. Rank held MoonLake Immunotherapeutics as of Q2 2026.

Based on ExodusPoint Capital Management's 13F filing for Q2 2026, filed 14 Aug 2026.